The American College of Lifestyle Medicine has published a new expert consensus statement affirming evidence-based lifestyle interventions as foundational, primary, and adjunctive treatments for major ...
Internet use is part of daily life for many people in work, social interaction, entertainment, shopping, and many other ...
A new medical large language model (LLM) achieved over 91% accuracy in identifying female participants diagnosed with major ...
EXXUA addresses frequent causes of treatment discontinuation with first-line SSRIs and SNRIs Now commercially available through retail pharmacies and participating Aytu RxConnect® pharmacies to ...
New TMS biomarkers combined with machine learning accurately classified major depressive disorder. Learn more about this ...
GlobalData on MSN
J&J’s Caplyta doubles remission rate in MDD patients
J&J presented the new analysis from three Phase III trials of Caplyta in MDD.
Find out how vagus nerve stimulation delivers durable symptom relief and quality of life gains in treatment resistant depression patients.
The FDA clears ProlivRx at-home neuromodulation for adjunctive major depressive disorder treatment in adults with inadequate antidepressant response.
Depression, one of the most prevalent mental health disorders worldwide, is characterized by persistent feelings of sadness, impaired daily functioning and a loss of interest in daily activities, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback